Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326567 | 0.91 | P2RY12 (0.50) | P2RY12ALDH1A1CYP3A4CYP2C9KDM4E | |
| SCHEMBL3584927 | 0.89 | P2RY12 (0.51) | P2RY12ALDH1A1CYP3A4CYP2C9KDM4E | |
| SCHEMBL3328353 | 0.88 | P2RY12 (0.50) | P2RY12ALDH1A1CYP3A4CYP2C9KDM4E | |
| SCHEMBL4115398 | 0.85 | P2RY12 (0.61) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL3328139 | 0.84 | P2RY12 (0.51) | P2RY12ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4007118 | 0.83 | ALDH1A1 (0.58) | P2RY12ALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL3326970 | 0.81 | L3MBTL1 (0.52) | P2RY12ALDH1A1CYP3A4CYP2C9KDM4E | |
| SCHEMBL3226916 | 0.79 | ALDH1A1 (0.55) | P2RY12ALDH1A1CYP3A4CYP2C9KDM4E | |
| SCHEMBL3327054 | 0.79 | P2RY12 (0.56) | P2RY12ALDH1A1CYP3A4CYP2C9KDM4E | |
| SCHEMBL3594018 | 0.78 | P2RY12 (0.77) | P2RY12CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069350-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-2044050-A1 | NEW PYRIDINE ANALOGUES | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039437-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008004946-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039437-A1 | New Pyridine Analogues III | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885ALDH1A1 1928/4885CYP3A4 202/4885 |
| US-20100069350-A1 | New Pyridine Analogues III | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885ALDH1A1 1691/4885CYP3A4 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.